Advance online publication

The latest articles are published online ahead of print (AOP) on a weekly basis. These online versions are definitive and may be cited using the digital object identifier (DOI).

Top

18 August 2017


News and Analysis

From the analyst's couch

Pulling away from the pack in drug launches | PDF (249 KB)

Published online: 18 August 2017 | doi:10.1038/nrd.2017.122

This analysis of US drug launches from the past decade indicates that commercial success has become more difficult to achieve, owing to factors such as increased competition, greater challenges in achieving therapeutic differentiation and payer pressures.

Top

Research Highlight

Inflammatory diseases: An IL-9 solution to inflammation resolution | PDF (977 KB)

Published online: 18 August 2017 | doi:10.1038/nrd.2017.164

Top

11 August 2017


News and Analysis

Biobusiness Briefs

Regulatory watch: Structural and procedural characteristics of international regulatory authorities | PDF (102 KB)

Published online: 11 August 2017 | doi:10.1038/nrd.2017.135

Top

Research Highlights

Antibacterial agents: New routes to tuberculosis treatment | PDF (113 KB)

Published online: 11 August 2017 | doi:10.1038/nrd.2017.156

Cancer immunotherapy: Searching in the immune checkpoint black box | PDF (708 KB)

Published online: 11 August 2017 | doi:10.1038/nrd.2017.163

In brief

Anticancer agents: Fighting resistance | PDF (92 KB)

Published online: 11 August 2017 | doi:10.1038/nrd.2017.157

Immunotherapy: CAR T cells in glioblastoma | PDF (92 KB)

Published online: 11 August 2017 | doi:10.1038/nrd.2017.158

Systems medicine: Understanding wellness and disease | PDF (92 KB)

Published online: 11 August 2017 | doi:10.1038/nrd.2017.159

Cancer: Inhibiting ROCK in neuroblastoma | PDF (92 KB)

Published online: 11 August 2017 | doi:10.1038/nrd.2017.160

Top

04 August 2017


Comment: NIH Centers for Accelerated Innovations Program: principles, practices, successes and challenges

Elliott M. Antman, Paul E. Di Corleto, Mason W. Freeman, Tomas Ganz, David E. Golan, Roger Kitterman, Joseph Loscalzo, Mark Low, Erin McKenna, Alan C. O'Connor, Michael Palazzolo, John Parrish, Ofer Reizes, Robert S. Ross, Cheryl Vaughan, D. Geoffrey Vince, Lesley Watts & for the NIH Centers for Accelerated Innovations

Published online: 04 August 2017 | doi:10.1038/nrd.2017.131

Commercializing innovations in academic environments is notoriously challenging. Here, we describe the progress of the NIH Centers for Accelerated Innovations program — initiated in 2013 to address these challenges — which we believe could help set a new standard for the early-stage commercialization of biomedical innovations in academic environments.

Top

21 July 2017


Reviews

Heart regeneration and repair after myocardial infarction: translational opportunities for novel therapeutics

Thomas J. Cahill, Robin P. Choudhury & Paul R. Riley

Published online: 21 July 2017 | doi:10.1038/nrd.2017.106

Regeneration of the heart by cardiomyocyte reconstitution represents an attractive approach to treat heart failure. Here, Riley and colleagues discuss recent insights into the biology of heart regeneration and highlight emerging therapeutic regenerative strategies for heart failure. Challenges and considerations in the translation of regenerative therapies into the clinic are discussed.

Senescent cells: an emerging target for diseases of ageing

Bennett G. Childs, Martina Gluscevic, Darren J. Baker, Remi-Martin Laberge, Dan Marquess, Jamie Dananberg & Jan M. van Deursen

Published online: 21 July 2017 | doi:10.1038/nrd.2017.116

Cellular senescence is causally linked to ageing and has been implicated in a variety of age-related diseases. Here, van Deursen and colleagues review the characteristics of senescent cells and highlight evidence for a role of these cells in diseases, including cancer, atherosclerosis and osteoarthritis. Emerging strategies for therapeutically targeting senescent cells and the associated challenges are discussed.

Top

14 July 2017


Review

Opportunities for therapeutic antibodies directed at G-protein-coupled receptors

Catherine J. Hutchings, Markus Koglin, William C. Olson & Fiona H. Marshall

Published online: 14 July 2017 | doi:10.1038/nrd.2017.91

G protein-coupled receptors (GPCRs) are key drug targets. In this article, Marshall and colleagues discuss the progress made towards generating GPCR-targeting antibodies, including which antigen formats and antibody platforms have been most successful. They review the current pipeline and outline outstanding challenges in antibody generation.

Top

07 July 2017


News and Analysis

From the analyst's couch

What is the right amount to spend on biopharma R&D? | PDF (270 KB)

Published online: 07 July 2017 | doi:10.1038/nrd.2017.114

This analysis investigates whether some companies may be negatively affecting their overall commercial success by aiming to maintain steady earnings per share growth and/or a target ratio of R&D spending to sales.

Top

Review

Remyelination therapies: a new direction and challenge in multiple sclerosis

Jason R. Plemel, Wei-Qiao Liu & V. Wee Yong

Published online: 07 July 2017 | doi:10.1038/nrd.2017.115

Restoring damaged myelin could reverse the neurological effects observed in patients with multiple sclerosis. In this Review, Yong and colleagues discuss the progress made in remyelinating therapies, including novel and potential repurposed agents, and highlight the challenges in preclinical and clinical development for such drugs.

Top

23 June 2017


News and Analysis

From the analyst's couch

The multiple sclerosis market | PDF (214 KB)

Published online: 23 June 2017 | doi:10.1038/nrd.2017.107

This article discusses the impact of new drugs on the market for multiple sclerosis, including the recently approved immunomodulatory drug ocrelizumab and drugs in development such as sphingosine 1-phosphate receptor modulators and neurorestorative agents.

Top

19 May 2017


Review

Therapeutic targeting of the angiopoietin–TIE pathway

Pipsa Saharinen, Lauri Eklund & Kari Alitalo

Published online: 19 May 2017 | doi:10.1038/nrd.2016.278

The angiopoietin (ANG)–TIE growth factor receptor pathway regulates pathological vascular remodelling during inflammation, tumour angiogenesis and metastasis. It has become an attractive pharmacological target for oncological and ophthalmological indications, as well as sepsis, diabetic vasculopathies, organ transplantation and atherosclerosis. Here, Alitalo and colleagues provide an overview of the biology of the ANG–TIE pathway and discuss the development of therapeutics that target it.

Top

12 May 2017


Review

The antifungal pipeline: a reality check

John R. Perfect

Published online: 12 May 2017 | doi:10.1038/nrd.2017.46

Invasive fungal infections are a major medical concern, particularly in immunocompromised patients. In this Review, Perfect discusses the antifungal pipeline, including advances in the currently used drug classes, novel molecular targets, drugs that could be repurposed from other areas and the use of immune-directed therapies.

Top

28 April 2017


Comment: Bridging the translational innovation gap through good biomarker practice

Alain J. van Gool, Florence Bietrix, Eric Caldenhoven, Kurt Zatloukal, Andreas Scherer, Jan-Eric Litton, Gerrit Meijer, Niklas Blomberg, Andy Smith, Barend Mons, Jaap Heringa, Wim-Jan Koot, Martin J. Smit, Marian Hajduch, Ton Rijnders & Anton Ussi

Published online: 28 April 2017 | doi:10.1038/nrd.2017.72

Few biomarkers progress from discovery to become validated tools or diagnostics. To bridge this gap, three European biomedical research infrastructures — EATRIS-ERIC (focused on translational medicine), BBMRI-ERIC (focused on biobanking) and ELIXIR (focused on data sharing) — are paving the way to developing and sharing best practices for biomarker validation.

Top

12 September 2016


Corrigendum: Impact of genetically supported target selection on R&D productivity

Mark R. Hurle, Matthew R. Nelson, Pankaj Agarwal & Lon R. Cardon

Published online: 12 September 2016 | doi:10.1038/nrd.2016.187


Top

About AOP

Until print versions of AOP papers are published, they should be cited in the style "Nature Reviews Drug Discovery AOP, published online day month year; doi:10.1038/nrdXXX". Once the print version (identical to the AOP) is published, it should be cited as follows: "Nature Reviews Drug Discovery volume number, page range (year); doi:10.1038/nrdXXX".